Results 141 to 150 of about 17,710 (254)

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes, Lian F. van der Gang, Daphne S. Bakker, C. F. den Hartog Jager, Marlies de Graaf, Marjolein S. de Bruin‐Weller, Femke van Wijk, Edward F. Knol   +7 more
wiley   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

International Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo, Luca Mastorino, Luca Cangialosi, Davide Favre, Chiara Anna Fiasconaro, Yingying Liao, Federico Goso, Niccolò Siliquini, Giovanni Cavaliere, Pietro Quaglino, Simone Ribero, Michela Ortoncelli   +11 more
wiley   +1 more source

Evaluation of Small Airways Dysfunction With Dupilumab Using Airway Oscillometry in Uncontrolled Severe Asthma

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 264-266, March 2025.
Kirsten E. Stewart, Chris RuiWen Kuo, Rory Chan, Brian J. Lipworth   +3 more
wiley   +1 more source

Mucous Membrane Pemphigoid After Anti‐PD‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes

International Journal of Dermatology, EarlyView.
ABSTRACT Mucous membrane pemphigoid (MMP) following anti‐programmed cell death‐1 (PD‐1) therapy is rare but increasingly reported. Management of high‐ and low‐risk MMP in this setting and the potential oncologic trade‐offs remain poorly defined. We performed a narrative synthesis of all published cases of anti‐PD‐1‐associated MMP, following MEDLINE ...
Serena Dienes, Negar Esfandiari, Steven Daveluy   +2 more
wiley   +1 more source

Eosinophilic Organ Complications Associated with Dupilumab Therapy - Narrative Review and Current Evidence. [PDF]

J Asthma Allergy
Suter P, Buetler VA, Graf N, Pavlov N.
europepmc   +1 more source

Are Phenotypic Baseline Characteristics Related to Abolition of AHR After Benralizumab and Dupilumab?

Clinical &Experimental Allergy, EarlyView.
Philipp Suter, Robert Greig, Rory Chan, Brian J. Lipworth   +3 more
wiley   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I. Silverberg, Kim A. Papp, Diamant Thaçi, Marjolein S. De Bruin‐Weller, Adam Reich, Ketty Peris, Kirk Barber, Ryszard Galus, Andrzej Kaszuba, Matthew Zirwas, Walter K. Nahm, Gretel Trullenque, Laura Maintz, Sady Alpizar, Sang Wook Son, Vivian Laquer, Linda Stein Gold, Soo Yeon Cheong, Anna Ryzhkova, Agnes Drahos, Liliana Ulianov, Christophe Piketty   +24 more
wiley   +1 more source

Detection and Management of Eosinophilia in Asthmatic Adults and Children Receiving Dupilumab Treatment: A Focused Review. [PDF]

J Inflamm Res
Caminati M, Cefaloni F, Tenero L, De Corso E, Micheletto C, Piacentini G.   +5 more
europepmc   +1 more source

Care pathways for the selection of a biologic in severe asthma [PDF]

, 2017
Bousquet, Jean, Brusselle, Guy, Buhl, Roland, Busse, William W, Cruz, Alvaro A, Djukanovic, Ratko, Domingo, Christian, Gow, Andrew Menzies, Hanania, Nicola A, Humbert, Marc, Phipatanakul, Wanda, Wahn, Ulrich, Wechsler, Michael E   +12 more
core   +2 more sources

scRNA‐Seq reveals anti‐lymphoma immune responses in mogamulizumab‐associated skin eruptions

Journal of the European Academy of Dermatology and Venereology, EarlyView.
CCR4 was expressed in malignant clones and regulatory T cells in untreated CTCL, that were decreased in MAR. Malignant clones in MAR showed a silenced phenotype with decreases in central memory markers SELL and CCR7, and GTP‐binding member GIMAP7 and upregulation of MMP2 inhibitor TIMP2 and tumour suppressor gene RUNX3.
Shannon Meledathu, Agata Kurowski, Malini P. Naidu, Jonas Adalsteinsson, Shane A. Meehan, Natalia Alkon, Lauren R. Port, Sumanth Chennareddy, Emry R. Cohenour, Grace Christensen, Jonah Shulman, Nicholas Gulati, Constanze Jonak, Patrick M. Brunner   +13 more
wiley   +1 more source